ClinicalTrials.gg
RecruitingNCT06526195TEAM-HFUpdated Nov 5, 2026

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

An interventional study of CardioMEMS HF System and HeartMate 3 Left Ventricular Assist System in Heart Failure, Heart Diseases and Cardiovascular Diseases, sponsored by Abbott Medical Devices. Recruiting at 70 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Nov 5, 2026Site recruiting status changed2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
850
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Heart Failure by Abbott — 6 open to participants now, 9 under way, none of them phase 3. Heart Failure · Abbott.

Planned enrollment
10th of 72
850 · median 136
Started
2024
with 1 other
No phase
62 of 120
2 open now
Registered
116th of 120
by date

Among the 120 studies in Heart Failure by Abbott, this one is the 10th largest by planned enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2024, is one of 62 with no phase, and was the 116th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 120 studies in Heart Failure by Abbott are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Heart Failure by Abbott, or all of them as a file.
02

Study summary

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

Read the detailed description

Patients with heart failure (HF) suffer from a high degree of morbidity and mortality. Left ventricular assist device (LVAD) therapy has become the standard of care for the treatment of advanced HF patients who are deemed to be dependent on continuous intravenous inotropes, extending life expectancy, enhancing overall quality of life, and improving functional capacity. However, use of LVADs in ambulatory, non-inotrope dependent advanced HF population is limited. Elevated mean pulmonary artery pressure (PAP) secondary to left ventricular failure has emerged as a potential predictor of increased mortality risk for patients refractory to maximally tolerated guideline directed medical therapy (GDMT). In these patients, left ventricular failure with elevated mean PAP may represent objective criteria to identify advanced HF patients requiring heart replacement therapies such as LVAD.

The TEAM-HF IDE trial will enroll approximately 850 subjects with New York Heart Association (NYHA) Class IIIB/IV HF who had a prior heart failure hospitalization and an elevated mean PAP secondary to left ventricular failure. Elevated mean PAP will be identified using an implanted PAP monitoring sensor, the CardioMEMS PA Sensor. All subjects enrolled can have a previously implanted CardioMEMS PA Sensor or, if not, will be implanted with the CardioMEMS PA Sensor after enrollment. The overall objectives of TEAM-HF trial are two-fold: 1) To determine whether PAP can objectively identify patients most at risk for worsening HF and therefore most likely to benefit from earlier intervention with LVAD therapy and 2) To determine the benefit of LVAD therapy in non-inotrope advanced HF patients with elevated mean PAP refractory to GDMT.

The trial will include approximately 75 global sites and consists of a Randomized Arm and a Single Arm Registry.

The TEAM-HF Randomized Arm is a prospective, randomized, open-label study of the HeartMate 3 (HM3) left ventricular assist system (LVAS) versus continued GDMT in non-inotrope dependent HF patients. The objectives of the Randomized Arm are 1) To establish an objective disease-state criteria to trigger referral for a HM3 LVAS and 2) Demonstrate improvement in survival when non-inotrope dependent advanced HF patients are treated with the HM3 LVAS compared to being managed on medical therapy alone.

The TEAM-HF Single Arm Registry is a prospective, single-arm, open-label study of non-inotrope dependent HF patients who do not meet a mean PAP threshold after GDMT optimization. The objective of the Single Arm Registry is to characterize the progression of patients with non-inotrope dependent HF without elevated PAP.

03

Conditions studied

  • Heart Failure
  • Heart Diseases
  • Cardiovascular Diseases
  • Pulmonary Hypertension

Keywords

  • Heart Failure
  • Left Ventricular Assist Device (LVAD)
  • Guideline Directed Medical Therapy (GDMT)
  • Non-inotrope Dependent
  • Pulmonary Artery Pressure
  • Hemodynamic Monitoring
  • Medical Management
  • CardioMEMS
  • HeartMate 3 (HM3)
  • Ambulatory Advanced Heart Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has provided written by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure
  2. ≤30% and Cardiac Index ≤ 2.5 L/min/m²
  3. Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or \<50% of predicted peak VO2 value)
  4. Class IIIB or NYHA Class IV
  5. Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months
  6. Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant
  7. Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group

Randomization Criteria:

  1. Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.
  2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
  3. mean PAP ≥ 30 mmHg.
  4. The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant.

Single Arm Registry Criteria:

  1. Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.
  2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
  3. mean PAP \<30 mmHg

Exclusion criteria

Exclusion Criteria:

  1. Subject is \< 18 years of age at the time of .
  2. Dependent on IV inotrope in the last 30 days.
  3. to HM3 LVAS or CardioMEMS HF system.
  4. Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.
  5. Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.
  6. Existence of ongoing MCS.
  7. Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.
  8. History of any solid organ transplant.
  9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.
  10. Presence of an active, uncontrolled infection.
  11. Complex congenital heart disease.
  12. Currently Pregnant or capable of becoming Pregnant and Unwilling to Use with LVAD.
  13. History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (>1 episode) pulmonary embolism and/or deep vein thrombosis.
  14. Planned VAD or Bi-VAD support prior to enrollment.
  15. Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:

    1. An ≥ 2.0 not due to anticoagulation therapy
    2. An \< 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.
    3. proven liver cirrhosis.
    4. Need for chronic renal replacement therapy.
    5. History of severe (COPD) defined by Forced Expiratory Volume \< 30% predicted.
    6. History of cerebrovascular disease with significant (> 80%) uncorrected internal carotid stenosis.
    7. Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.
  16. Any condition other than HF that could limit survival to less than 24 months.
  17. Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
850 participants (estimated)

Study arms

  • Experimental
    Randomized Arm - HM3 Group

    Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the HM3 group will receive the device within 14 days of randomization.

    Device: CardioMEMS HF System · Device: HeartMate 3 Left Ventricular Assist System · Other: Guideline Medical Directed Therapy

  • Experimental
    Randomized Arm - Control Group

    Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the control group will continue their medical therapy per established heart failure guidelines.

    Device: CardioMEMS HF System · Other: Guideline Medical Directed Therapy

  • Experimental
    Single Arm Registry

    Patients who do not meet the mean PAP threshold (mean PAP \<30 mmHg) and are enrolled in the single arm will continue their medical therapy per established heart failure guidelines.

    Device: CardioMEMS HF System · Other: Guideline Medical Directed Therapy

Interventions

  • DeviceCardioMEMS HF System

    The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

    Also known as: CardioMEMS, CardioMEMS PA Sensor

  • DeviceHeartMate 3 Left Ventricular Assist System

    The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.

    Also known as: HM3

  • OtherGuideline Medical Directed Therapy

    Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

    Also known as: GDMT

06

What researchers measure

Primary outcomes

  1. Survival at 2 years free of disabling stroke, reoperation to replace the device, or worsening HF requiring listing for urgent heart transplantation or mechanical circulatory support, enrollment into hospice, or dependence on IV inotropes

    The powered primary endpoint will be analyzed at 2 years following the Com-Nougue method and will be compared between the HM3 Group (HM3 LVAD) and the Control Group (GDMT) within the Intention-to-treat (ITT) population.

    Time frame: 2 years

Secondary outcomes

  1. Rate of Safety Outcomes at 1-year

    The powered secondary endpoint of Rate of Safety Outcomes at 1-year will be evaluated within the Intention-to-treat (ITT) population against a pre-specified performance goal. Components consist of the following: 1. Heart failure hospitalization 2. Major Adverse Event (MAE) including: * Stroke * Non-surgical bleeding (\>14 days post implant) requiring hospitalization * Renal failure requiring hospitalization * Driveline infection requiring hospitalization

    Time frame: 1 year

  2. Survival at 2 years

    The powered secondary endpoint of survival at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population.

    Time frame: 2 years

  3. Quality of life score assessed with the Kansas City Cardiomyopathy Questionnaire

    The secondary endpoint of Quality-of-life score at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Quality of life at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. The KCCQ scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Improvement of KCCQ by at least 10 points is considered clinically significant.

    Time frame: 2 years

  4. Six-minute walk distance

    The secondary endpoint of six-minute walk distance at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of six-minute walk distance at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

    Time frame: 2 years

  5. Hospitalizations for HF and/or Urgent HF Visit

    The secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

    Time frame: 2 years

  6. Days alive and outside of the hospital

    The secondary endpoint of days alive and outside of the hospital at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of days alive and outside of the hospital at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

    Time frame: 2 years

  7. All-cause hospitalizations

    The secondary endpoint of all-cause hospitalizations at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all-cause hospitalizations at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

    Time frame: 2 years

  8. All adverse events (including all strokes) regardless of severity

    The secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

    Time frame: 2 years

Other outcomes

  1. Finkelstein-Schoenfeld Win Ratio

    The Finkelstein-Schoenfeld Win Ratio will be explored at 5 years as an additional analysis with the following hierarchy: 1. Survival 2. Days alive outside of the hospital 3. Quality of Life assessed with the KCCQ (considered a tie if within 10 points) 4. Functional Capacity (Six-minute walk distance) The Finkelstein-Schoenfeld Win Ratio will be analyzed between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the Finkelstein-Schoenfeld Win Ratio will be descriptively analyzed between the Single Arm and both the HM3 Group and Control Group of the Randomized Arm separately.

    Time frame: 5 years

  2. Survival free of urgent LVAD or transplant

    This additional descriptive analysis at 5-years will be performed to evaluate the proportion of patients who are alive and free of device replacement or transplant in the HM3 Group compared to the Single Arm Registry (de novo implant or transplant)

    Time frame: 5 years

07

Study locations

68 of 70 sites recruiting
08

References and documents

Publications

  • Jabr D, Pedersen R, Dahal A, Paredes-Flores M, Valika AA, Sulemanjee NZ, Pauwaa S, Dia M, Macaluso GP, Pillarella J, Joshi A, Sciamanna C, Dela Cruz M, Cotts WG, Matarieh AA, Gandhi HA, Hussain SM, Ezidinma AP, Narang N, Chau VQ. Hemodynamic Profiles During Pulmonary Artery Pressure Sensor Implantation: Risk Stratification in Chronic Heart Failure With Reduced Ejection Fraction. J Card Fail. 2025 Nov;31(11):1621-1630. doi: 10.1016/j.cardfail.2025.09.002. Epub 2025 Sep 27. PubMed 41022266 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2029, 57 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 57 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Jul 29, 2024
StartActual
Dec 13, 2024
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2032
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. 2 sites changed recruiting status (1 now withdrawn, 1 now terminated)
Show 2 sites
  • Banner-University Medical Center Phoenix · Phoenix, United StatesRecruiting→Withdrawn
  • University of Kentucky · Lexington, United StatesRecruiting→Terminated
Show 2 added (2 United States)
  • University of Pittsburgh Medical Center (UPMC) · Philadelphia, United States
  • Virginia Commonwealth University · Richmond, United States
Nov 5, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • Banner-University Medical Center Phoenix · Phoenix, United StatesContact removed A•••@bannerhealth.com · •••2052Contact removed (no phone or email listed)
  • University of Kentucky · Lexington, United StatesContact removed b•••@uky.edu · •••5366Contact removed (no phone or email listed)
  • New Mexico Heart Institute · Albuquerque, United StatesContact person changed (no phone or email listed)
  • Carolinas Medical Center · Charlotte, United StatesContact person changed (no phone or email listed)
  • The Stern Cardiovascular Foundation · Memphis, United StatesContact person changed (no phone or email listed)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    2 sites added. 2 sites changed recruiting status (1 now withdrawn, 1 now terminated)
    Show 2 sites
    • Banner-University Medical Center Phoenix · Phoenix, United StatesRecruiting→Withdrawn
    • University of Kentucky · Lexington, United StatesRecruiting→Terminated
    Show 2 added (2 United States)
    • University of Pittsburgh Medical Center (UPMC) · Philadelphia, United States
    • Virginia Commonwealth University · Richmond, United States
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Banner-University Medical Center Phoenix · Phoenix, United StatesContact removed A•••@bannerhealth.com · •••2052Contact removed (no phone or email listed)
    • University of Kentucky · Lexington, United StatesContact removed b•••@uky.edu · •••5366Contact removed (no phone or email listed)
    • New Mexico Heart Institute · Albuquerque, United StatesContact person changed (no phone or email listed)
    • Carolinas Medical Center · Charlotte, United StatesContact person changed (no phone or email listed)
    • The Stern Cardiovascular Foundation · Memphis, United StatesContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06526195
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Dec 13, 2024
Primary completion
Sep 2029 (estimated)
Completion
Sep 2032 (estimated)
Last update
Nov 5, 2026

Study contacts

Nourdine Chakouri, PhD
Contact
nourdine.chakouri@abbott.com
925-989-5982
Kelly O'Connell, PhD
study director · Abbott

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion